| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) - (IMmotion010) | Renal Cell Carcinoma | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) - (IMpower030) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) - (IMbrave050) | Hepatocellular carcinoma | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | Crenezumab - (CREAD 2) | Alzheimer’s disease | Phase 3 | Trial Discontinued | Intravenous | Neurology |
| Roche Holding AG ADR | VENCLEXTA (venetoclax) - (CANOVA) | Multiple Myeloma | Phase 3 | Oral | Oncology | |
| Roche Holding AG ADR | Crenezumab - (CREAD 1) | Alzheimer’s disease | Phase 3 | Trial Discontinued | Intravenous | Neurology |
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) - (IMvoke010) | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | Faricimab (RG7716) | Neovascular age related macular degeneration (nAMD) | Phase 3 | Intravitreal | Opthalmic |